Seongnam, South Korea Saturday, December 27, 2025, 17:00 Hrs [IST] ...
Clinical Trials Arena on MSN
Senhwa to evaluate Pidnarulex and Enhertu in Phase Ib trial
The combination with Enhertu aims to improve treatment outcomes for HER2-low patients and expand therapeutic options.
Patients should be selected for treatment with Enhertu in combination with pertuzumab based on confirmed HER2-positive status or HER2 gene amplification (IHC 3+ or ISH+).
CX-5461 is the first G-quadruplex (G4) stabilizer in development. It has shown promising activity in early-phase trials for ...
SurvivorNet on MSN
Enhertu significantly cuts recurrence rates for women with high-risk HER2-positive breast cancer — the practice-changing DESTINY-Breast05 trial
For women with a specific type of breast cancer known as HER2-positive (HER2+), any residual (leftover) disease after primary ...
From respiratory infection to fatal neurological disease, EHV-1 demands rapid PCR diagnosis, and detection protocols impact ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback